BACKGROUND: Prostate cancer harboring cyclin-dependent kinase 12 (CDK12) abnormalities is a hot topic due to its distinctive clinical features, such as sensitivity to immune checkpoint inhibitors. In the last few years, precision medicine using comprehensive genome sequencing has become familiar, and the era of precision oncology has arrived in the field of prostate cancer. This study aimed to present the demographic characteristics of patients with CDK12 alterations. METHODS: In 12 patients with detected CDK12 alterations in our hospital between 2015 and 2021, we evaluated their genomic features and clinical course. CDK12 allelic status was classified into three groups: monoallelic loss, potentially biallelic loss, and biallelic loss based on the genome analyses. RESULTS: Seven patients already had metastatic cancer at the time of diagnosis, and all 12 patients had Gleason grade ≥ 4. Most cases of biallelic loss or potentially biallelic loss were metastatic cancers at the initial staging, and all these cases were categorized into Gleason grade 5. Two of the 12 patients had BRCA2/RB1 co-loss, and the other two had whole genome duplication. Five patients had a long-term survival of > 6 years, but two patients died within 4 years of diagnosis. CONCLUSION: This is the first Japanese prostate cancer case series with CDK12 alterations. CDK12-altered prostate cancer is a heterogeneous disease, and accumulating cases with detailed information leads to precision oncology.
BACKGROUND: Prostate cancer harboring cyclin-dependent kinase 12 (CDK12) abnormalities is a hot topic due to its distinctive clinical features, such as sensitivity to immune checkpoint inhibitors. In the last few years, precision medicine using comprehensive genome sequencing has become familiar, and the era of precision oncology has arrived in the field of prostate cancer. This study aimed to present the demographic characteristics of patients with CDK12 alterations. METHODS: In 12 patients with detected CDK12 alterations in our hospital between 2015 and 2021, we evaluated their genomic features and clinical course. CDK12 allelic status was classified into three groups: monoallelic loss, potentially biallelic loss, and biallelic loss based on the genome analyses. RESULTS: Seven patients already had metastatic cancer at the time of diagnosis, and all 12 patients had Gleason grade ≥ 4. Most cases of biallelic loss or potentially biallelic loss were metastatic cancers at the initial staging, and all these cases were categorized into Gleason grade 5. Two of the 12 patients had BRCA2/RB1 co-loss, and the other two had whole genome duplication. Five patients had a long-term survival of > 6 years, but two patients died within 4 years of diagnosis. CONCLUSION: This is the first Japanese prostate cancer case series with CDK12 alterations. CDK12-altered prostate cancer is a heterogeneous disease, and accumulating cases with detailed information leads to precision oncology.
Authors: Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Ethan S Sokol; Dean Pavlick; Garrett M Frampton; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Tamara L Lotan; Drew M Pardoll; Jon H Chung; Emmanuel S Antonarakis Journal: Oncologist Date: 2019-07-10
Authors: Melissa A Reimers; Steven M Yip; Li Zhang; Marcin Cieslik; Mallika Dhawan; Bruce Montgomery; Alexander W Wyatt; Kim N Chi; Eric J Small; Arul M Chinnaiyan; Ajjai S Alva; Felix Y Feng; Jonathan Chou Journal: Eur Urol Date: 2019-10-20 Impact factor: 20.096
Authors: Bastien Nguyen; Jose Mauricio Mota; Subhiksha Nandakumar; Konrad H Stopsack; Emily Weg; Dana Rathkopf; Michael J Morris; Howard I Scher; Philip W Kantoff; Anuradha Gopalan; Dmitriy Zamarin; David B Solit; Nikolaus Schultz; Wassim Abida Journal: Eur Urol Date: 2020-04-19 Impact factor: 20.096
Authors: Michael T Schweizer; Gavin Ha; Roman Gulati; Landon C Brown; Rana R McKay; Tanya Dorff; Anna C H Hoge; Jonathan Reichel; Pankaj Vats; Deepak Kilari; Vaibhav Patel; William K Oh; Arul Chinnaiyan; Colin C Pritchard; Andrew J Armstrong; R Bruce Montgomery; Ajjai Alva Journal: JCO Precis Oncol Date: 2020-04-21
Authors: Goutam Chakraborty; Joshua Armenia; Ying Z Mazzu; Subhiksha Nandakumar; Konrad H Stopsack; Mohammad O Atiq; Kazumasa Komura; Lina Jehane; Rahim Hirani; Kalyani Chadalavada; Yuki Yoshikawa; Nabeela A Khan; Yu Chen; Wassim Abida; Lorelei A Mucci; Gwo-Shu Mary Lee; Gouri J Nanjangud; Philip W Kantoff Journal: Clin Cancer Res Date: 2019-12-03 Impact factor: 12.531
Authors: Johann de Bono; Joaquin Mateo; Karim Fizazi; Fred Saad; Neal Shore; Shahneen Sandhu; Kim N Chi; Oliver Sartor; Neeraj Agarwal; David Olmos; Antoine Thiery-Vuillemin; Przemyslaw Twardowski; Niven Mehra; Carsten Goessl; Jinyu Kang; Joseph Burgents; Wenting Wu; Alexander Kohlmann; Carrie A Adelman; Maha Hussain Journal: N Engl J Med Date: 2020-04-28 Impact factor: 91.245
Authors: Peter Priestley; Jonathan Baber; Martijn P Lolkema; Neeltje Steeghs; Ewart de Bruijn; Charles Shale; Korneel Duyvesteyn; Susan Haidari; Arne van Hoeck; Wendy Onstenk; Paul Roepman; Mircea Voda; Haiko J Bloemendal; Vivianne C G Tjan-Heijnen; Carla M L van Herpen; Mariette Labots; Petronella O Witteveen; Egbert F Smit; Stefan Sleijfer; Emile E Voest; Edwin Cuppen Journal: Nature Date: 2019-10-23 Impact factor: 49.962
Authors: Yi-Mi Wu; Marcin Cieślik; Robert J Lonigro; Pankaj Vats; Melissa A Reimers; Xuhong Cao; Yu Ning; Lisha Wang; Lakshmi P Kunju; Navonil de Sarkar; Elisabeth I Heath; Jonathan Chou; Felix Y Feng; Peter S Nelson; Johann S de Bono; Weiping Zou; Bruce Montgomery; Ajjai Alva; Dan R Robinson; Arul M Chinnaiyan Journal: Cell Date: 2018-06-14 Impact factor: 41.582
Authors: Pasquale Rescigno; Bora Gurel; Rita Pereira; Mateus Crespo; Jan Rekowski; Mattia Rediti; Maialen Barrero; Joaquin Mateo; Diletta Bianchini; Carlo Messina; Maria D Fenor de la Maza; Khobe Chandran; Juliet Carmichael; Christina Guo; Alec Paschalis; Adam Sharp; George Seed; Ines Figueiredo; Maryou Lambros; Susana Miranda; Ana Ferreira; Claudia Bertan; Ruth Riisnaes; Nuria Porta; Wei Yuan; Suzanne Carreira; Johann S de Bono Journal: Clin Cancer Res Date: 2020-09-28 Impact factor: 13.801